AP-HP, Service d'Aide Médicale d'Urgence (SAMU) de Paris and Paris Sudden Death Expertise Center, Université Paris Descartes, Paris, France.
Emergency Department, Cliniques universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium.
JAMA. 2018 Feb 27;319(8):779-787. doi: 10.1001/jama.2018.0156.
Bag-mask ventilation (BMV) is a less complex technique than endotracheal intubation (ETI) for airway management during the advanced cardiac life support phase of cardiopulmonary resuscitation of patients with out-of-hospital cardiorespiratory arrest. It has been reported as superior in terms of survival.
To assess noninferiority of BMV vs ETI for advanced airway management with regard to survival with favorable neurological function at day 28.
DESIGN, SETTINGS, AND PARTICIPANTS: Multicenter randomized clinical trial comparing BMV with ETI in 2043 patients with out-of-hospital cardiorespiratory arrest in France and Belgium. Enrollment occurred from March 9, 2015, to January 2, 2017, and follow-up ended January 26, 2017.
Participants were randomized to initial airway management with BMV (n = 1020) or ETI (n = 1023).
The primary outcome was favorable neurological outcome at 28 days defined as cerebral performance category 1 or 2. A noninferiority margin of 1% was chosen. Secondary end points included rate of survival to hospital admission, rate of survival at day 28, rate of return of spontaneous circulation, and ETI and BMV difficulty or failure.
Among 2043 patients who were randomized (mean age, 64.7 years; 665 women [32%]), 2040 (99.8%) completed the trial. In the intention-to-treat population, favorable functional survival at day 28 was 44 of 1018 patients (4.3%) in the BMV group and 43 of 1022 patients (4.2%) in the ETI group (difference, 0.11% [1-sided 97.5% CI, -1.64% to infinity]; P for noninferiority = .11). Survival to hospital admission (294/1018 [28.9%] in the BMV group vs 333/1022 [32.6%] in the ETI group; difference, -3.7% [95% CI, -7.7% to 0.3%]) and global survival at day 28 (55/1018 [5.4%] in the BMV group vs 54/1022 [5.3%] in the ETI group; difference, 0.1% [95% CI, -1.8% to 2.1%]) were not significantly different. Complications included difficult airway management (186/1027 [18.1%] in the BMV group vs 134/996 [13.4%] in the ETI group; difference, 4.7% [95% CI, 1.5% to 7.9%]; P = .004), failure (69/1028 [6.7%] in the BMV group vs 21/996 [2.1%] in the ETI group; difference, 4.6% [95% CI, 2.8% to 6.4%]; P < .001), and regurgitation of gastric content (156/1027 [15.2%] in the BMV group vs 75/999 [7.5%] in the ETI group; difference, 7.7% [95% CI, 4.9% to 10.4%]; P < .001).
Among patients with out-of-hospital cardiorespiratory arrest, the use of BMV compared with ETI failed to demonstrate noninferiority or inferiority for survival with favorable 28-day neurological function, an inconclusive result. A determination of equivalence or superiority between these techniques requires further research.
clinicaltrials.gov Identifier: NCT02327026.
在心肺复苏的高级心脏生命支持阶段,与经口气管插管(ETI)相比,球囊面罩通气(BMV)是一种用于气道管理的技术,其操作相对简单。已有研究报道,BMV 在存活率方面优于 ETI。
评估 BMV 与 ETI 在 28 天有良好神经功能的存活率方面的非劣效性。
设计、地点和参与者:这项在法国和比利时进行的多中心随机临床试验,比较了 2043 例院外心肺骤停患者中 BMV 与 ETI 的应用。招募工作于 2015 年 3 月 9 日开始,2017 年 1 月 2 日结束,随访于 2017 年 1 月 26 日结束。
将参与者随机分为 BMV 组(n = 1020)或 ETI 组(n = 1023)进行初始气道管理。
主要结局为 28 天的良好神经功能预后,定义为神经功能分类(CPC)1 或 2 级。选择了 1%的非劣效性边界。次要终点包括住院存活率、28 天存活率、自主循环恢复率以及 ETI 和 BMV 的困难或失败率。
在 2043 例随机患者中(平均年龄 64.7 岁,女性 665 例[32%]),2040 例(99.8%)完成了试验。在意向治疗人群中,BMV 组 1018 例患者中有 44 例(4.3%)和 ETI 组 1022 例患者中有 43 例(4.2%)在 28 天时有良好的功能存活(差异为 0.11%[单侧 97.5%CI,-1.64%至无穷大];P 非劣效性 = .11)。BMV 组有 294 例(28.9%)患者存活至入院,而 ETI 组有 333 例(32.6%)患者存活至入院(差异为-3.7%[95%CI,-7.7%至 0.3%]),28 天全球存活率(BMV 组 55 例[5.4%],ETI 组 54 例[5.3%])差异无统计学意义(差异为 0.1%[95%CI,-1.8%至 2.1%])。并发症包括气道管理困难(BMV 组 1027 例中有 186 例[18.1%],ETI 组 996 例中有 134 例[13.4%];差异为 4.7%[95%CI,1.5%至 7.9%];P = .004)、失败(BMV 组 1028 例中有 69 例[6.7%],ETI 组 996 例中有 21 例[2.1%];差异为 4.6%[95%CI,2.8%至 6.4%];P < .001)和胃内容物反流(BMV 组 1027 例中有 156 例[15.2%],ETI 组 999 例中有 75 例[7.5%];差异为 7.7%[95%CI,4.9%至 10.4%];P < .001)。
在院外心肺骤停患者中,与 ETI 相比,使用 BMV 未能证明在 28 天有良好神经功能的存活率方面具有非劣效性或劣效性,这是一个不确定的结果。需要进一步的研究来确定这两种技术之间的等效性或优越性。
clinicaltrials.gov 标识符:NCT02327026。